<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04840745</url>
  </required_header>
  <id_info>
    <org_study_id>A55_03PK2023</org_study_id>
    <nct_id>NCT04840745</nct_id>
  </id_info>
  <brief_title>The Safety and Pharmacokinetic/Pharmacodynamic Study of CKD-841 in Postmenopausal Female, Phase 1</brief_title>
  <official_title>A Randomized, Single-blinded, Parallel Design Phase I Clinical Trial to Investigate the Safety and Pharmacokinetics/Pharmacodynamics of CKD-841 A-1, CKD-841 D or Leuplin Inj. After Subcutaneous Injection in Postmenopausal Female</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, single-blinded, parallel design phase I clinical trial to investigate the&#xD;
      safety and pharmacokinetics/pharmacodynamics of CKD-841 A-1, CKD-841 D or Leuplin Inj. after&#xD;
      subcutaneous injection in postmenopausal female&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the safety and pharmacokinetics/pharmacodynamics of CKD-841 A-1, CKD-841 D or&#xD;
      Leuplin Inj. 3.75 mg after subcutaneous injection in postmenopausal female&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK(Cmax)</measure>
    <time_frame>From before injection to up to 1008 hours post injection</time_frame>
    <description>Cmax(Maximum concentration of drug in plasma) of Leuprorelin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK(AUClast)</measure>
    <time_frame>From before injection to up to 1008 hours post injection</time_frame>
    <description>AUClast(Area under the plasma drug concentration-time curve to last measurement) of Leuprorelin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK(AUCinf)</measure>
    <time_frame>From before injection to up to 1008 hours post injection</time_frame>
    <description>AUCinf(Area under the plasma drug concentration-time curve extrapolated to infinity) of Leuprorelin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK(AUC7-t)</measure>
    <time_frame>From before injection to up to 1008 hours post injection</time_frame>
    <description>AUC7-t(Area under the plasma drug concentration-time curve from 7 days to last measurement) of Leuprorelin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK(CL/F)</measure>
    <time_frame>From before injection to up to 1008 hours post injection</time_frame>
    <description>CL/F(Apparent Clearance) of Leuprorelin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK(Vd/F)</measure>
    <time_frame>From before injection to up to 1008 hours post injection</time_frame>
    <description>Vd/F(Apparent Volume of Distribution) of Leuprorelin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK(Tmax)</measure>
    <time_frame>From before injection to up to 1008 hours post injection</time_frame>
    <description>Tmax(Time to Cmax/Time to Emax) of Leuprorelin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK(t1/2)</measure>
    <time_frame>From before injection to up to 1008 hours post injection</time_frame>
    <description>t1/2(Terminal elimination half-life) of Leuprorelin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PD(AUEC0-42d below baseline)</measure>
    <time_frame>From before injection to up to 1008 hours post injection</time_frame>
    <description>AUEC0-42d below baseline((AUEC that is below the baseline from 0 h to 42 days)) of the rate of change(%) relative to the base of the LH (Luteinizing Hormone), FSH (Follicular Stimulating Hormone), and Estradiol respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PD(AUEC0-28d below baseline)</measure>
    <time_frame>From before injection to up to 1008 hours post injection</time_frame>
    <description>AUEC0-28d below baseline(AUEC that is below the baseline from 0 h to 28 days) of the rate of change(%) relative to the base of the LH (Luteinizing Hormone), FSH (Follicular Stimulating Hormone), and Estradiol respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PD(Area under the response (% change from baseline) curve)</measure>
    <time_frame>From before injection to up to 1008 hours post injection</time_frame>
    <description>AUEC(Area under the response (% change from baseline) curve) above baseline of the rate of change(%) relative to the base of the LH (Luteinizing Hormone), FSH (Follicular Stimulating Hormone), and Estradiol respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PD(Tmax)</measure>
    <time_frame>From before injection to up to 1008 hours post injection</time_frame>
    <description>Tmax(Time to Cmax/Time to Emax) of the rate of change(%) relative to the base of the LH (Luteinizing Hormone), FSH (Follicular Stimulating Hormone), and Estradiol respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PD(Tmin)</measure>
    <time_frame>From before injection to up to 1008 hours post injection</time_frame>
    <description>Tmin(Time to Emin) of the rate of change(%) relative to the base of the LH (Luteinizing Hormone), FSH (Follicular Stimulating Hormone), and Estradiol respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PD(Emax)</measure>
    <time_frame>From before injection to up to 1008 hours post injection</time_frame>
    <description>Emax(Maximum % change from baseline of LH/FSH/Estradiol) of the rate of change(%) relative to the base of the LH (Luteinizing Hormone), FSH (Follicular Stimulating Hormone), and Estradiol respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PD(Emin)</measure>
    <time_frame>From before injection to up to 1008 hours post injection</time_frame>
    <description>Emin(Minimum % change from baseline of LH/FSH/Estradiol) of the rate of change(%) relative to the base of the LH (Luteinizing Hormone), FSH (Follicular Stimulating Hormone), and Estradiol respectively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Assessment by evaluating adverse events(AEs).</measure>
    <time_frame>From day1 to day 56</time_frame>
    <description>Assessment of the safety of subjects by evaluating adverse events(AEs).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Early Puberty</condition>
  <arm_group>
    <arm_group_label>CKD-841 A-1(=leuprorelin acetate 3.75mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational drug(=CKD-841 A-1) is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD-841 A-1(=leuprorelin acetate 1.88mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational drug(=CKD-841 A-1) is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD-841 D(=leuprorelin acetate 2.92mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational drug(=CKD-841 D) is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leuplin Inj.(=leuprorelin acetate 3.75mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Investigational drug(=Leuplin Inj.)is prescribed single injection dose by subcutaneous to 8 of randomized subjects once.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-841 A-1 3.75mg</intervention_name>
    <description>Single injection, subcutaneous injection</description>
    <arm_group_label>CKD-841 A-1(=leuprorelin acetate 3.75mg)</arm_group_label>
    <other_name>CKD-841</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-841 A-1 1.88mg</intervention_name>
    <description>Single injection, subcutaneous injection</description>
    <arm_group_label>CKD-841 A-1(=leuprorelin acetate 1.88mg)</arm_group_label>
    <other_name>CKD-841</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-841 D 2.92mg</intervention_name>
    <description>Single injection, subcutaneous injection</description>
    <arm_group_label>CKD-841 D(=leuprorelin acetate 2.92mg)</arm_group_label>
    <other_name>CKD-841</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuplin Inj. 3.75 mg</intervention_name>
    <description>Single injection, subcutaneous injection</description>
    <arm_group_label>Leuplin Inj.(=leuprorelin acetate 3.75mg)</arm_group_label>
    <other_name>Leuplin.Inj</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy menopausal female&#xD;
&#xD;
          -  β-hCG is negative at screening and before administration of investigational drug&#xD;
&#xD;
          -  Infertility by sterilization operation before 5 months from screening excluding&#xD;
             ovarian cancer, uterine cancer etc.&#xD;
&#xD;
          -  Bwt ≥ 50Kg and Body Mass Index (BMI) ≥ 18.5 and &lt; 28.0&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or current condition of disease related to Hepato-biliary system, renal&#xD;
             system, nervous system, mental illness, immune system, respiratory system, endocrine&#xD;
             system, hemato-oncology, circulatory system, musculoskeletal system or except for&#xD;
             that, significant clinical disease&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus in the last three months&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  History of taking medicine such as Leuprorelin acetate or similar affiliation drug&#xD;
             within 12 weeks before administration of investigational drug&#xD;
&#xD;
          -  Has hypersensitivity to the active ingredient or excipients or same affiliation drug&#xD;
             of the investigational drug, hypersensitivity of a medicine contained gelatin&#xD;
             especially&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Soo Park, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Soo Park, Ph.D</last_name>
    <phone>82-2-2228-0401</phone>
    <email>minspark@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Yonsei-ro, Seodaemun-gu 50-1</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CKD-841</keyword>
  <keyword>Postmenopausal</keyword>
  <keyword>Leuplin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Puberty, Precocious</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

